Abstract
The efficacy of diallyl trisulfide (DATS) against arsenic (As) induced dyslipidemia in the plasma and livers of rats was studied. Oral administration of As [5 mg/kg of body weight (BW)/day] for 4 weeks showed significant (p<0.05) increases in TC, LDL-C, VLDL-C, FFA, PL, and TG levels and the activity of HMG-CoA reductase in the plasma and liver, with significant (p<0.05) reductions in levels of HDL-C hepatic ubiquinones and activities of LCAT and LPL in the plasma and liver. Oral administration of DATS (80 mg/kg of BW) for 4 weeks in As intoxicated rats significantly (p<0.05) reduced plasma and liver TC, FFA, TGs, VLDL-C, and LDL-C levels, and the activity of HMG-CoA reductase, and significantly (p<0.05) increased the activities of LCAT and LPL and the levels of HDL-C and ubiquinone in the livers of rats. DATS protects against As-induced dyslipidemia in rats.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
